Previous Close | 22.79 |
Open | 22.81 |
Bid | 22.71 x 800 |
Ask | 22.80 x 900 |
Day's Range | 22.68 - 22.87 |
52 Week Range | 21.36 - 24.83 |
Volume | |
Avg. Volume | 49,981 |
Market Cap | N/A |
Beta (5Y Monthly) | 1.03 |
PE Ratio (TTM) | 5.07 |
EPS (TTM) | 4.48 |
Earnings Date | Jan 17, 2025 |
Forward Dividend & Yield | 1.31 (5.78%) |
Ex-Dividend Date | Nov 08, 2024 |
1y Target Est | N/A |
Amgen's (AMGN) investigational drug MariTide is a good opportunity for the company to enter the obes
Citi analyst Keith Horowitz raised the firm’s price target on Truist Financial (TFC) to $51 from $47 and keeps a Neutral rating on the shares. The firm believes Truist’s cost of equity will support peak multiples in the near term. The underlying story at Truist skews positive given its strong capital position and presence in attractive markets that are poised to benefit from a rebound in loan demand, the analyst tells investors in a research note. However, Citi remains cautious on the timing for